Atea Pharmaceuticals (AVIR) Income towards Parent Company (2019 - 2026)

Atea Pharmaceuticals' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$45.4 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 32.59% year-over-year to -$45.4 million; the TTM figure through Mar 2026 stood at -$169.5 million (down 21.53% YoY), while the FY2025 annual figure was -$158.3 million, up 5.96% from the prior year.
• Income towards Parent Company was -$45.4 million for Q1 2026 at Atea Pharmaceuticals, down from -$44.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$8.1 million in Q3 2022 to a low of -$63.2 million in Q1 2024.
• Historically, Income towards Parent Company has averaged -$36.7 million across 5 years, with a median of -$35.5 million in 2023.
• Biggest YoY gain for Income towards Parent Company was 71.39% in 2022; the steepest drop was 2136.06% in 2022.
• A 5-year view of Income towards Parent Company shows it stood at -$34.4 million in 2022, then retreated by 13.75% to -$39.2 million in 2023, then advanced by 14.35% to -$33.5 million in 2024, then slumped by 33.76% to -$44.9 million in 2025, then decreased by 1.28% to -$45.4 million in 2026.
• The last three Income towards Parent Company figures came in at -$45.4 million (Q1 2026), -$44.9 million (Q4 2025), and -$42.0 million (Q3 2025), per Business Quant data.